Bill > SB1214

This bill expands the scope of pharmacists' medical practice in Arizona by allowing them to independently order, perform, and interpret certain FDA-authorized and CLIA-waived tests, and initiate treatment for specific health conditions for patients 12 years and older. The authorized conditions include influenza, strep throat, COVID-19 and other coronavirus illnesses, HIV prophylaxis, and emerging public health threats. The Arizona State Board of Pharmacy must develop a statewide written protocol addressing documentation, patient screening, exclusion criteria, treatment instructions, and pharmacist training. Pharmacists must use evidence-based clinical guidelines, refer patients to primary care providers when necessary, and notify the patient's primary care provider within 72 hours of initiating treatment. The bill requires pharmacists to maintain treatment records for seven years, obtain parental consent for minors, and display a notice that the testing and treatment are performed without direct physician oversight. Importantly, pharmacists cannot independently treat patients with opioids or make clinical judgments beyond the established protocol. An advisory committee comprising pharmacists, physicians, a patient advocate, and a nurse practitioner will help develop these protocols, with the committee's mandate set to expire on December 31, 2026.

Government Affairs, Health and Social Services

https://apps.azleg.gov/BillStatus/BillOverview/82557